Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Potential drug–drug interactions among U.S. adults treated with nirmatrelvir/ritonavir: A cross‐sectional study of the National Covid Cohort Collaborative (N3C)

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy(2023)10.1002/phar.2860Source: DataRank Database

Potential drug–drug interactions among U.S. adults treated with nirmatrelvir/ritonavir: A cross‐sectional study of the National Covid Cohort Collaborative (N3C) is a dataset published in Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2023). On theSindex it has a DataRank of 0.597, placing it in the top 33% of the data-sharing corpus. It has been cited 9 times, with 6 citing works in its 1-hop citation network.

Top 33%percentile

0.597DataRank

Ranks in the top 33% for downstream scientific impact

Data paper Open Access9 citations · 6 citing works in its network

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (75 grants)Impact (FWCI 1.53)OA: greenTopics (52)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (1/3)

Dataset classification

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 58%Citation Network 42%

Base Score Contribution

0.345

From this paper's citation signal

Citation Network Contribution

0.252

From 6 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 6 citers.

Question
Journal of Clinical Psychopharmacology20247 citations15 referencesContributes 0.139
Frequency, type and severity of drug-related problems and pharmacist interventions in Paxlovid® prescribing: a descriptive analysis
International Journal of Clinical Pharmacy20242 citations25 referencesContributes 0.044
Potential drug interactions with nirmatrelvir/ritonavir in critically ill patients with COVID-19: a retrospective observational study
RPS Pharmacy and Pharmacology Reports20251 citations17 referencesContributes 0.041
Ritonavir: 25 Years’ Experience of Concomitant Medication Management. A Narrative Review
Infectious Diseases and Therapy202413 citations103 referencesContributes 0.026
Real-World Analysis of Potential Drug-Drug Interactions with Nirmatrelvir/Ritonavir Based on the Hospital Prescription Analysis (HPA) Database in 9 Cities of China
Infection and Drug Resistance20251 citations28 referencesContributes 0.025

Authors (5)

Hemalkumar B. Mehta ORCID,Jill Curran,Brian T. Garibaldi ORCID,G. Caleb Alexander ORCID,Xuya Xiao ORCID

Live enrichment

PubMed:37539477 PMC:PMC10838345 OpenAlex:https://openalex.org/W4385563576

NCATS NIH HHS

Grant: U24 TR002306

NIGMS NIH HHS

Grant: U54 GM115677

NCATS NIH HHS

Grant: UL1 TR001412

NCATS NIH HHS

Grant: UL1 TR001433

NCATS NIH HHS

Grant: UL1 TR001449

NCATS NIH HHS

Grant: UL1 TR001453

NCATS NIH HHS

Grant: UL1 TR001863

NCATS NIH HHS

Grant: UL1 TR001872

NCATS NIH HHS

Grant: UL1 TR001881

NCATS NIH HHS

Grant: UL1 TR002384

NCATS NIH HHS

Grant: UL1 TR002541

NCATS NIH HHS

Grant: UL1 TR002550

NCATS NIH HHS

Grant: UL1 TR002556

NCATS NIH HHS

Grant: UL1 TR002736

NCATS NIH HHS

Grant: UL1 TR001409

NCATS NIH HHS

Grant: UL1 TR001442

NCATS NIH HHS

Grant: UL1 TR001876

NCATS NIH HHS

Grant: UL1 TR002001

NCATS NIH HHS

Grant: UL1 TR002489

NCATS NIH HHS

Grant: UL1 TR003096

NIGMS NIH HHS

Grant: U54 GM104940

NIGMS NIH HHS

Grant: U54 GM115428

NCATS NIH HHS

Grant: UL1 TR001422

NCATS NIH HHS

Grant: UL1 TR001439

NCATS NIH HHS

Grant: UL1 TR001998

NCATS NIH HHS

Grant: UL1 TR002537

NCATS NIH HHS

Grant: UL1 TR002649

NCATS NIH HHS

Grant: UL1 TR003107

NIGMS NIH HHS

Grant: U54 GM104938

NCATS NIH HHS

Grant: UL1 TR001860

NCATS NIH HHS

Grant: UL1 TR002003

NCATS NIH HHS

Grant: UL1 TR002243

NCATS NIH HHS

Grant: UL1 TR002538

NIGMS NIH HHS

Grant: U54 GM104941

NIGMS NIH HHS

Grant: U54 GM115516

NCATS NIH HHS

Grant: UL1 TR001414

NCATS NIH HHS

Grant: UL1 TR001427

NCATS NIH HHS

Grant: UL1 TR001436

NCATS NIH HHS

Grant: UL1 TR001866

NCATS NIH HHS

Grant: UL1 TR002319

NCATS NIH HHS

Grant: UL1 TR002389

NCATS NIH HHS

Grant: UL1 TR002529

NCATS NIH HHS

Grant: UL1 TR002553

NCATS NIH HHS

Grant: UL1 TR003015

NCATS NIH HHS

Grant: UL1 TR003142

NIGMS NIH HHS

Grant: U54 GM115371

NIGMS NIH HHS

Grant: U54 GM115458

NCATS NIH HHS

Grant: UL1 TR001425

NCATS NIH HHS

Grant: UL1 TR001445

NCATS NIH HHS

Grant: UL1 TR002366

NCATS NIH HHS

Grant: UL1 TR002494

NCATS NIH HHS

Grant: UL1 TR002645

NCATS NIH HHS

Grant: UL1 TR003167

NIA NIH HHS

Grant: K01 AG070329

NIGMS NIH HHS

Grant: U54 GM104942

NCATS NIH HHS

Grant: UL1 TR001430

NCATS NIH HHS

Grant: UL1 TR001873

NCATS NIH HHS

Grant: UL1 TR002014

NCATS NIH HHS

Grant: UL1 TR002345

NCATS NIH HHS

Grant: UL1 TR002378

NCATS NIH HHS

Grant: UL1 TR002544

NCATS NIH HHS

Grant: UL1 TR003017

NCATS NIH HHS

Grant: UL1 TR003098

NHLBI NIH HHS

Grant: T32 HL139426

NCATS NIH HHS

Grant: UL1 TR001420

NCATS NIH HHS

Grant: UL1 TR001450

NCATS NIH HHS

Grant: UL1 TR001855

NCATS NIH HHS

Grant: UL1 TR001878

NCATS NIH HHS

Grant: UL1 TR002240

NCATS NIH HHS

Grant: UL1 TR002369

NCATS NIH HHS

Grant: UL1 TR002373

NCATS NIH HHS

Grant: UL1 TR002377

NCATS NIH HHS

Grant: UL1 TR002535

NCATS NIH HHS

Grant: UL1 TR002733

NCATS NIH HHS

Grant: UM1 TR004556

FWCI

1.53

Citation Percentile

0.8%

Citation Trend

2023

2024

2025

2026

greenLicense: http://onlinelibrary.wiley.com/termsAndConditions#vor

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10838345/pdf/nihms-1922307.pdf

publisherhttps://accpjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/phar.2860

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10838345

journalhttps://doi.org/10.1002/phar.2860

Fields of Study

COVID-19 Clinical Research StudiesPharmacogenetics and Drug MetabolismPharmaceutical Practices and Patient OutcomesAdultHumansMaleAdolescentMiddle AgedAgedFemaleCOVID-19COVID-19 Drug TreatmentCross-Sectional StudiesRitonavirAntiviral AgentsLactamsLeucineNitrilesProline

MeSH Terms

COVID-19COVID-19 Drug TreatmentAdolescentAdultAgedAntiviral AgentsCross-Sectional StudiesFemaleHumansLactamsLeucineMaleMiddle AgedNitrilesProlineRitonavir

Keywords

MedicineRitonavirOdds ratioConfidence intervalCross-sectional studyCohortInternal medicineCohort studyViral loadHuman immunodeficiency virus (HIV)Family medicineDrug interactionsDrug safetyPatient SafetyAntiviralsSars-cov-2Nirmatrelvir/ritonavir

Sustainable Development Goals

SDG 0: Good health and well-being